VACC

Vaccitech plc [VACC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

VACC Stock Summary

In the News

04:30 24 Mar 2023 VACC

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.

04:01 24 Mar 2023 VACC

Vaccitech to Present at Upcoming September Investors Conferences

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.

01:33 24 Mar 2023 VACC

Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why

Vaccitech PLC Sponsored ADR (VACC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

01:48 24 Mar 2023 VACC

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies. In the VTP-.

04:15 24 Mar 2023 VACC

Vaccitech to Present at the Jefferies Healthcare Conference

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.

11:30 24 Mar 2023 VACC

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virtually.

07:57 24 Mar 2023 VACC

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Vaccitech (NASDAQ: VACC) is known to be the spin-off from Oxford University behind AstraZeneca Sars-Cov-2 vaccine.

08:00 24 Mar 2023 VACC

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.

11:30 24 Mar 2023 VACC

Wall Street Analysts Believe Vaccitech PLC Sponsored ADR (VACC) Could Rally 113%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Vaccitech PLC Sponsored ADR (VACC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

09:49 24 Mar 2023 VACC

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Vaccitech plc (NASDAQ: VACC) has announced an interim analysis of safety and efficacy data of VTP-300 from the HBV002 study, including a review of surface antigen (HBsAg) levels in chronic Hepatitis B patients. Data from an interim analysis of immunogenicity and safety in Groups 1 and 2 were recently reported at the 2021 AASLD The Liver Meeting.

VACC Financial details

Company Rating
Buy
Market Cap
111.52M
Income
11.42M
Revenue
38.25M
Book val./share
6.55
Cash/share
5.37
Dividend
-
Dividend %
-
Employees
72
Optionable
No
Shortable
Yes
Earnings
10 Nov 2022
P/E
7.05
Forward P/E
-
PEG
-0.7
P/S
2.1
P/B
0.33
P/C
0.4
P/FCF
-6.05
Quick Ratio
15.01
Current Ratio
15.58
Debt / Equity
0.13
LT Debt / Equity
0.03
-
-
EPS (TTM)
0.05
EPS next Y
-
EPS next Q
-
EPS this Y
187.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-63.87%
EPS Q/Q
-47.62%
-
-
-
-
SMA20
-6.76%
SMA50
12.2%
SMA100
-1.08%
Inst Own
26.81%
Inst Trans
0.36%
ROA
4%
ROE
5%
ROC
0.02%
Gross Margin
-
Oper. Margin
14%
Profit Margin
30%
Payout
-
Shs Outstand
37.3M
Shs Float
26.32M
-
-
-
-
Target Price
22
52W Range
2.02-7.45
52W High
-69.14%
52W Low
+8.01%
RSI
32.97
Rel Volume
7.97
Avg Volume
52.08K
Volume
415K
Perf Week
-25.77%
Perf Month
-28.71%
Perf Quarter
-30.54%
Perf Half Y
-33.74%
-
-
-
-
Beta
-
-
-
Volatility
0.27%, 0.22%
Prev Close
-21.74%
Price
2.1601
Change
-27.75%

VACC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2019-12-31 2021-12-31
Revenue per share
101.175.62
Net income per share
-371.62-1.07K
Operating cash flow per share
-231.46-683.86
Free cash flow per share
-237.61-707.91
Cash per share
239.944.49K
Book value per share
-471.115.29K
Tangible book value per share
-463.44.38K
Share holders equity per share
-471.115.29K
Interest debt per share
112.86207.57
Market cap
671.81K529.35K
Enterprise value
-8.98M-206.3M
P/E ratio
-0.04-0.01
Price to sales ratio
0.141.98
POCF ratio
-0.06-0.02
PFCF ratio
-0.06-0.02
P/B Ratio
-0.030
PTB ratio
-0.030
EV to sales
-1.86-769.79
Enterprise value over EBITDA
0.654.33
EV to operating cash flow
0.816.33
EV to free cash flow
0.796.12
Earnings yield
-26.36-96.09
Free cash flow yield
-16.85-63.72
Debt to equity
-1.830.11
Debt to assets
2.160.1
Net debt to EBITDA
0.74.34
Current ratio
2.8320.32
Interest coverage
-5.57-16.95
Income quality
0.620.64
Dividend Yield
00
Payout ratio
00
Sales general and administrative to revenue
2.1793.72
Research and developement to revenue
2.361.08
Intangibles to total assets
00.16
Capex to operating cash flow
0.030.04
Capex to revenue
-0.06-4.28
Capex to depreciation
-1.4-1.9
Stock based compensation to revenue
0.7561.52
Graham number
1.98K11.27K
ROIC
2.610.3
Return on tangible assets
-0.93-0.21
Graham Net
-561.634K
Working capital
10.5M215.61M
Tangible asset value
-22.08M208.5M
Net current asset value
-24.87M198.61M
Invested capital
-0.080.03
Average receivables
05.08M
Average payables
03.15M
Average inventory
00
Days sales outstanding
295.918.51K
Days payables outstanding
00
Days of inventory on hand
00
Receivables turnover
1.230.04
Payables turnover
00
Inventory turnover
00
ROE
0.79-0.2
Capex per share
-6.14-24.05

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-06-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
000.40.460.17
Net income per share
-0.64-0.610.070.420.22
Operating cash flow per share
-0.59-0.36-0.18-0.230.32
Free cash flow per share
-0.6-0.38-0.21-0.150.25
Cash per share
9.788.65.395.175.37
Book value per share
10.0210.136.86.846.55
Tangible book value per share
10.048.375.645.715.44
Share holders equity per share
10.0210.136.86.846.55
Interest debt per share
0.060.290.180.230.25
Market cap
417.78M276.61M193.39M165.55M119.19M
Enterprise value
175.75M69.78M-467.69K-18.16M-72.66M
P/E ratio
-6.56-4.5818.622.643.62
Price to sales ratio
11.94K-276.61K12.889.719.33
POCF ratio
-28.57-30.6-29.4-19.7210.03
PFCF ratio
-28.18-28.98-25.21-29.6612.58
P/B Ratio
1.681.10.770.650.49
PTB ratio
1.681.10.770.650.49
EV to sales
5.02K-69.78K-0.03-1.06-11.79
Enterprise value over EBITDA
-11.12-4.75-0.17-1.08-7.42
EV to operating cash flow
-12.02-7.720.072.16-6.11
EV to free cash flow
-11.85-7.310.063.25-7.67
Earnings yield
-0.04-0.050.010.090.07
Free cash flow yield
-0.04-0.03-0.04-0.030.08
Debt to equity
0.040.110.130.120.13
Debt to assets
0.040.10.120.110.11
Net debt to EBITDA
15.3114.07-69.91-10.97-19.59
Current ratio
30.0520.321418.615.58
Interest coverage
0-9268.84208.917.3
Income quality
0.920.6-2.53-0.531.45
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
353.46-9.79K0.240.38-1.81
Research and developement to revenue
103.83-5.67K0.640.571.7
Intangibles to total assets
00.160.150.150.15
Capex to operating cash flow
0.010.060.17-0.33-0.2
Capex to revenue
-5.77506-0.070.16-0.39
Capex to depreciation
-1.94-1.41-1.132.83-2.03
Stock based compensation to revenue
249.6-6.54K0.270.160.18
Graham number
12.0111.763.278.065.71
ROIC
0.070.11-0.01-0.13-0.06
Return on tangible assets
-0.06-0.060.010.060.04
Graham Net
9.557.654.974.74.74
Working capital
248.19M215.61M214.3M214.13M204.59M
Tangible asset value
249.91M208.5M209.87M212.29M202.46M
Net current asset value
246.8M198.61M197.8M196M187.29M
Invested capital
0.010.030.030.030.03
Average receivables
4.8M014.57M19.97M13.77M
Average payables
4.76M03.54M4.57M3.44M
Average inventory
00000
Days sales outstanding
14.39K-562.41K137.2489.92153.07
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.0100.6610.59
Payables turnover
00000
Inventory turnover
00000
ROE
-0.06-0.060.010.060.03
Capex per share
-0.01-0.02-0.030.08-0.06

VACC Frequently Asked Questions

What is Vaccitech plc stock symbol ?

Vaccitech plc is a GB stock and trading under the symbol VACC

What is Vaccitech plc stock quote today ?

Vaccitech plc stock price is $2.1601 today.

Is Vaccitech plc stock public?

Yes, Vaccitech plc is a publicly traded company.

Something similar